NCT01181700已完成1 期
An Open Study To Estimate The Plasma Pharmacokinetics Of PF-00241939 Administered Via Oral Inhalation Using Dry Powder Inhalers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Plasma pharmacokinetic parameters: AUClast and Cmax.
研究概览
简要总结
The purpose of this study is to investigate the time course of PF-00241939 concentrations in the blood following dosing by oral inhalation using dry powder inhalers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and/or female subjects between the ages of 21 and 55 years.
- •Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- •Pregnant or nursing females.
- •A positive urine drug screen.
研究组 & 干预措施
Treatment A
Experimental
干预措施: Treatment A (Drug)
Treatment B
Experimental
干预措施: Treatment B (Drug)
Treatment C
Experimental
干预措施: Treatment C (Drug)
Treatment D
Active Comparator
干预措施: Treatment D (Drug)
Treatment E
Active Comparator
干预措施: Treatment E (Drug)
Treatment F
Active Comparator
干预措施: Treatment F (Drug)
Treatment G
Active Comparator
干预措施: Treatment G (Drug)
结局指标
主要结局
Plasma pharmacokinetic parameters: AUClast and Cmax.
时间窗: 36 hours
次要结局
- Plasma pharmacokinetic parameters: AUC24, AUCinf, Tmax and half-life.(36 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Estimate the Time Course of PF-00241939 Concentration in the Blood Following Dosing by Oral Inhalation From Dry Powder InhalersPharmacokineticsNCT00867282Pfizer36
已完成
1 期
A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers.HealthyNCT00862667Pfizer36
已完成
1 期
Study To Estimate The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder InhalersHealthyNCT00977015Pfizer36
已完成
1 期
A Study Estimating The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder InhalersHealthyNCT00928278Pfizer36
已完成
1 期
This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder InhalersHealthyNCT01272375Pfizer48